Findings on Bacillus Calmette–Guérin (BCG) for Superficial Bladder Cancer | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Frontiers | Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer | Pharmacology
RECENT KNOWLEDGE ON BCG ́ S MECHANISM OF ACTION IN THE TREATMENT OF SUPERFICIAL BLADDER CANCER | Semantic Scholar
Frontiers | BCG Against SARS-CoV-2: Second Youth of an Old Age Vaccine? | Pharmacology
The mechanism of action of BCG therapy for bladder cancer—a current perspective | Semantic Scholar
Bacteria that activate natural killer cells to eliminate bladder cancer
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer | Oncotarget
Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect - ScienceDirect
Nonmuscle invasive bladder cancer: a primer on immunotherapy | Maruf | Cancer Biology & Medicine
Mechanisms of BCG induced anti-tumor immunity | Sloan Kettering Institute
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An U | ITT
Mechanisms of immune evasion in bladder cancer | SpringerLink
The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine | npj Vaccines
Investigating the STING Pathway to Explain Mechanisms of BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications - IOS Press
Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin - European Urology
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studies - ScienceDirect
Study Clarifies How Bladder Cancer Treatment Works | Memorial Sloan Kettering Cancer Center
Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette–Guérin | Future Oncology
Cancers | Free Full-Text | Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives | HTML
Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model
Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer | Semantic Scholar
Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non–Muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of
The battle field between BCG and Immune cells: The mechanism of... | Download Scientific Diagram
